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Edited by Giulio Superti-FurgaAbstract Toll-like receptors (TLRs) are crucial components of
the innate immune system, coupling pathogen recognition to a
cellular response. We used the MAPPIT mammalian two-hybrid
technique to investigate protein–protein interactions in the early
steps in TLR signalling. A partial TLR-adaptor interaction map
was constructed conﬁrming several known but also documenting
novel interactions. We show that the TLR adaptor Mal is critical
for linking Myeloid Diﬀerentiation primary response protein 88
(MyD88) to TLR2 and TLR4. Analysis of the contributions of
the diﬀerent sub-domains of MyD88-adaptor-like protein
(Mal) and MyD88 in adaptor homo- and hetero-dimerisation
provides an initial mechanistic insight in this bridging function
of Mal.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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One of the ﬁrst steps in pathogen clearance is the activation
of signalling pathways by Toll-like receptors (TLRs). At pres-
ent, 10 TLRs are identiﬁed in the human genome. Typical
TLR ligands are bacterial lipopolysaccharide (LPS), recogni-
sed by TLR4 [1], bacterial lipopeptides (TLR2) [2], double
stranded RNA (TLR3) [3], ﬂagellin (TLR5) [4] and CpG mo-
tifs in DNA (TLR9) [5]. Next to ligand binding, adaptor mol-
ecules are recruited to the receptor through homotypic TIR–
TIR (Toll/IL-1 receptor domain) domain interactions.
MyD88 (Myeloid Diﬀerentiation primary response protein
88) was the ﬁrst adaptor to be described [6], and is thought
to be used by every TLR except TLR3. Subsequently, three
more TIR-containing adaptors were found: Mal/TIRAP
(MyD88-adaptor-like protein/TIR domain containing adap-
tor-like protein), which, based on knock-out studies, appears
to be important in TLR2 and TLR4 signalling and exerts moreAbbreviations: IFN, interferon; LR, Leptin receptor; Mal, MyD88-
adaptor-like protein; MyD88, Myeloid Diﬀerentiation primary re-
sponse protein 88; Sarm, Sterile alpha and HEAT-Armadillo motifs
containing protein; STAT, Signal Transducer and Activator of Tran-
scription; TIR, Toll/IL-1 Receptor; TLR, Toll-like receptor; Tram,
TRIF-related adaptor molecule; Trif, TIR-domain containing adaptor
inducing IFNb
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doi:10.1016/j.febslet.2007.01.026or less the same function as MyD88 [7–10], Trif/Ticam-1 (TIR-
domain containing adaptor inducing interferon-b/TIR con-
taining adaptor molecule), an adaptor recruited by both
TLR3 and TLR4 and responsible for activation of IRF3
[11,12] and Tram/Ticam-2 (Trif-related adaptor molecule/
TIR containing adaptor molecule-2), known to act as a bridg-
ing adaptor between TLR4 and Trif [13,14]. Recently, Sarm
(sterile alpha and HEAT-Armadillo motifs containing pro-
tein), a potential ﬁfth TLR adaptor molecule, was shown to
negatively regulate Trif-dependent Toll-Like receptor signal-
ling [15]. The usage of diﬀerent adaptors by diﬀerent receptors
partially provides a molecular basis for the speciﬁcity of the
immune reaction against a given pathogen. However, the exact
modalities of this speciﬁcity are not yet fully understood [16].
Further downstream signalling can be primarily divided into
a MyD88-dependent branch, which ultimately leads to activa-
tion of NF-jB and mitogen-activated protein kinases (MAPK)
like p38 and Jun N-terminal Kinase (JNK) and a MyD88-
independent branch resulting in phosphorylation of Interferon
Regulatory Factors (IRFs) and expression of interferon-b
(IFN-b). The MyD88-dependent pathway is initiated by
recruitment of IRAK-4 (IL-1 receptor associated kinase-4) to
the activated receptor [17] through a homotypic interaction
with the death domain of MyD88. Next, IRAK-4 phosphory-
lates IRAK-1 [18] and activated IRAK-1 associates together
with TRAF-6 (TNF-a receptor-associated factor 6) [19] into
a complex with TAB (TAK-1 binding) proteins and TAK-1
(TGF-b-activated kinase-1) [20]. This complex is a branching
point for the activation of NF-jB and induction of the MAPK
pathway. Activation of TLR3 and TLR4 also engages a
MyD88-independent pathway. Recruitment of Trif to the acti-
vated receptor leads to activation of TBK1 (TANK-binding
kinase-1) and IKKe, which are essential for IRF-3 phosphory-
lation and nuclear translocation and subsequent induction of
IFN-b [21]. In this report we make use of the mammalian
two-hybrid method MAPPIT (MAmmalian Protein–Protein
Interaction Trap) [22] to study the modalities of TIR–TIR
interactions involved in the early steps of TLR signalling.2. Material and methods
2.1. Constructs
Generation of the pMG2 and pMG2-SVT prey vectors were de-
scribed earlier [23]. Human full-length MyD88 was ampliﬁed using
primers 1 and 2 on the pCDNA3-MyD88-AU1 plasmid (gift of Dr.
Muzio). After EcoRI–XbaI digestion, the fragment was cloned in the
pMG2 vector, resulting in pMG2-MyD88. The TIR domain of
MyD88 was cloned in an analogous manner into the pMG2 vectorblished by Elsevier B.V. All rights reserved.
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and pMG2-MalTIR plasmids were generated by ampliﬁcation of
Mal and the TIR domain of Mal from the pDC304–Mal vector (gift
from Dr. O’Neill) with primers 5–6 and 7–8 respectively, and EcoRI/
XbaI or BsteII/XbaI digestion. The TIR domain of Sarm was ampliﬁed
using primers 9–10 on HepG2 cDNA followed by EcoRI/XbaI diges-
tion. This resulted in the pMG2-SarmTIR vector. The pMG2-Tram
vector was generated by ampliﬁcation of full-length Tram using primer
11–12 on Hek293 cDNA. After BsteII/XhoI digestion, the fragment
was cloned in the pMG2 vector.
Generation of the human LepR-bait constructs in the pcDNA5/
FRT vector was described before [22], and this construct was named
pCLL. The pCLL-MyD88 plasmid was generated by ampliﬁcation
of full-length MyD88 from the MyD88-AU1 vector using primer pairs
13–14. After BamHI/NotI digestion, the fragments were cloned in the
pCLL vector. The pCLL-Mal and pCLL-Tram plasmids were gener-
ated in an analogous manner using primers 15–16 and 17–18, respec-
tively. The intracellular domains of Toll-Like receptor 2, 3, 4, 5, 7, 9
were ampliﬁed using primer sets 19–20, 21–22, 23–24, 25–26, 27–28,
29–30 on MRC5 cDNA (TLR2), the pFLAG CMV1 – TLR3 vector
(gift from Dr. O’Neill), the pFLAG CMV1 – TLR4 vector (gift from
Dr. O’Neill), and RZPD clones HU3_p983D0273D (TLR5), IR-
ATp970B1256D (TLR7) IRATp970H1255D (TLR9) respectively.
After BamHI/NotI digestion, the fragments were cloned into the pCLL
vector.
The MalP125H and MyD88P200H mutant vectors were generated
by PCR based mutagenesis using primers 31–32 and 33–34, respec-
tively (Quikchange site-directed mutagenesis method, Stratagene).
The pcDNA5-TAP2-CIS vector was generated by ampliﬁcation of
TAP2-CIS using primers 35–36 on the pMET7-TAP2-ﬂag vector,
which was described earlier [24], followed by a KpnI/NotI based liga-
tion into the pCDNA5-FRT-TO vector (Invitrogen). Mal was ampli-
ﬁed using primers 37–38 on the pDC304–Mal vector and EcoRI/
NotI based ligation into the pcDNA5-TAP2-CIS vector resulted in
the pcDNA5-Mal-ﬂag plasmid.
The pXP2d2-rPAPI-luciferase reporter, originating from the rPAPI
(rat pancreatitis associated protein I) promoter was used as previously
described [22]. The pNFconluc reporter was a gift of Dr. A. Israel.
2.2. Cell culture, transfection, reporter assays and expression controls
Cell culture conditions, transfection procedures and luciferase assays
for Hek293T cells were previously described [25]. For a typical lucifer-
ase experiment, 4 · 105 cells were seeded in 6-well plates 24 h before
transfecting them overnight with the desired constructs together with
the luciferase reporter gene. Cells were left untreated (negative control
NC) or were stimulated overnight with 100 ng/ml leptin followed by
measurement of luciferase activity in cell lysates by chemiluminescence.
Prey expression was examined by Western Blot using anti-FLAG
mouse monoclonal antibody (Sigma), on lysates of transfected cells.
All results are representative for at least three independent transfection
experiments.2.3. Co-immunoprecipitation
Approximately 2 · 106 Hek293T cells were transfected with diﬀerent
combinations of MAPPIT bait vector pCLL-TLR4ic, MyD88-prey
plasmid, and an expression vector encoding Mal. Cleared lysates (mod-
iﬁed RIPA lysis buﬀer: 200 mM NaCl, 50 mM Tris–HCl PH8, 0.05%
SDS, 2 mM EDTA, 1% NP40, 0.5% DOC, Complete Protease Inhib-
itor Cocktail (Roche)) were incubated with a mixture of two rat
anti-mouse LR monoclonal antibodies (4 lg/ml) [26] and protein G-se-
pharose (Amersham Biosciences). After immunoprecipitation, SDS–
PAGE and Western Blotting, interactions were detected using anti-
ﬂag-tag antibody (Sigma), anti-HA (HA-11, CRPinc) and anti-
mouse-HRP (horseradish peroxidase) (Amersham Biosciences).2.4. Fluorescence microscopy and immunocytochemistry
Hek293T cells were ﬁxed with 3% paraformaldehyde in phosphate-
buﬀered saline (Invitrogen) for 20 min at room temperature. Next, cells
were permeabilised in 0.1% Triton X-100, washed in phosphate-buf-
fered saline, incubated with anti-ﬂag antibody (Sigma) for 1 h at
37 C and following several washes in phosphate buﬀered saline incu-
bated with Alexaﬂuor488-conjugated goat anti-mouse antibody
(Molecular Probes) at room temperature. Nuclei were DAPI stained.
Microscopic images were captured with a Zeiss Axiovert 200 epiﬂuo-rescence microscope equipped with an Axiocam cooled CCD camera
and processed using AXIOVISION software.3. Results
3.1. MAPPIT concept
MAPPIT (MAmmalian Protein–Protein Interaction Trap),
a mammalian two-hybrid method [22], was used to study pro-
tein–protein interactions in the TLRs pathway (Fig. 1A). In
brief, we made a C-terminal fusion of a given ‘bait’ protein
with a leptin receptor that is deﬁcient in STAT3 recruitment.
The ‘prey’ protein on the other hand is linked to a series of
four functional STAT3 recruitment sites of the gp130 chain.
Association of bait and prey and ligand stimulation leads to
STAT3 activation and induction of a STAT3-responsive lucif-
erase reporter (rPAPI-Luci). Expression of all the diﬀerent
preys used throughout this study was checked by Western blot
analysis using an anti-FLAG antibody (Supplementary data).
Bait expression was assayed by FACS analysis using an anti-
LR antibody (Supplementary data) (see Table 1).
We cloned all TLR adaptors both as bait and as prey, and
the intracellular part of selected TLRs as bait. An overview
of all tested adaptor/adaptor and adaptor/TLR interactions
can be found in Table 2. Well-documented interactions like
homo- or hetero-oligomerisation of Mal and MyD88 or inter-
action of Tram with TLR4 were conﬁrmed. In addition, new
interactions were found, including the association of the TIR
domain of Sarm with MyD88 and Tram. Other new ﬁndings
will be discussed in more detail below. No MAPPIT signals
were detected using Trif as bait or as prey. This cannot be ex-
plained by an a-speciﬁc eﬀect of Trif on the MAPPIT readout
since Trif over-expression did not inﬂuence an established
interaction-dependent signal (data not shown). We also ruled
out cytotoxic eﬀects by the Trif-prey since its over-expression
did not lead to increased annexin V binding, a marker for
apoptosis (data not shown). We also constructed a Trif-prey
with a C-terminal fusion of the gp130 tail to exclude interfer-
ence of a N-terminal Trif fusion protein with protein–protein
interactions, but again no positive signals could be observed
(data not shown). Strikingly, the subcellular expression of
the Trif-prey was limited to a perinuclear compartment, much
in contrast to functional prey molecules (Fig. 1B). Since MAP-
PIT measures interactions in the sub-plasmamembranary
space, this ﬁnding provides a likely explanation for the lack
of Trif-dependent signals in MAPPIT experiments.
We also monitored the eﬀect of bait expression on endoge-
nous TLR signalling (Fig. 1C). The MyD88-bait and, to a les-
ser extent, the Mal-bait were able to activate the NF-jB
pathway in a ligand independent manner. These data show
that the MAPPIT setup forms functional signalling complexes
at the cell membrane, underscoring its relevance to study TLR
signalling.
3.2. Homo- and hetero-oligomerisation of Mal and MyD88
Mal and MyD88 both have a C-terminal TIR interaction
domain (Toll/IL-1 receptor domain), a property shared with
all TLRs and their adaptors. This TIR domain is thought to
be the critical interaction domain for recruitment of TLR
adaptors to their cognate receptors and for adaptor dimerisa-
tion. MyD88 bears an additional N-terminal Death Domain
linked to the TIR domain by a short intermediate region.
Fig. 1. (A) MAPPIT principle. MAPPIT, a cytokine receptor-based two hybrid method, makes use of a bait protein, C-terminally fused to a leptin
receptor that is deﬁcient in STAT3 recruitment by a Y1138F mutation, and a prey protein linked to a string of four functional STAT3 recruitment
sites of the gp130 chain. Interaction of bait and prey leads to a ligand-dependent complementation of STAT3 activity that can be measured with a
STAT3-responsive luciferase reporter (rPAPI-luci). TLR adaptors were used as bait or prey, while the intracellular parts of selected TLRs were used
as bait. (B) Trif-prey localisation. Hek293T cells were transfected with either Trif-prey, Mal-prey or SVT-prey lacking its nuclear localisation
sequence . Cells were ﬁxed and incubated with anti-ﬂag antibody. Prey expression was visualised with a ﬂuorescent secondary antibody (anti-mouse
IgG-alexa488). Nuclei were DAPI stained. (C) TLR adaptor bait expression activates NF-jB pathway. Hek293T cells were transfected with diﬀerent
TLR adaptor bait-constructs (1 lg) and a NF-jB responsive luciferase reporter (pNF-conluci). Twenty-four hours after transfection the transfected
cells were stimulated with leptine (100 ng/ml) for another 24 h or left untreated (NS). Mean Luciferase activity + S.D. of triplicate measurements is
plotted.
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ositol 4,5-bisphosphate (PIP2) binding domain, which medi-
ates Mal recruitment to the plasma membrane [27]. As seen
in Table 2, the TLR adaptors Mal and MyD88 clearly can
form homo- and hetero-dimers, a well-established early event
in TLR signalling. To elucidate which domains of these adapt-
ors are essential in this dimerisation process we mutated a pro-
line to histidine in the TIR domain of Mal (P125H) and
MyD88 (P200H), a mutation known to abrogate TLR signal-
ling [1]. We also generated a prey construct only containing the
C-terminal TIR domain of MyD88 and Mal.
Strikingly, when analysing the interaction properties of the
Mal-bait (Fig. 2A), we observed a drastic eﬀect of the Pﬁ H
mutation. Mutation of the TIR domain of either bait or prey
is suﬃcient to abrogate interaction. These data conﬁrm that
the TIR domain of Mal and MyD88 is necessary and suﬃcient
for heterodimerisation. These properties were conﬁrmed using
MyD88 as bait (Fig. 2B).
Much in contrast, Mal homodimerisation depended on its
N-terminal part in addition to TIR-TIR binding. No interac-
tion was observed when using the Mal-bait combined with a
MalTIR-prey only containing the C-terminal TIR region
(Fig. 2A). However, this prey is still functional since clear asso-
ciation of the MyD88-bait and the MalTIR-prey was observed
(Fig. 2B). Mutation of a single TIR domain leads to complete
loss of homodimerisation (Fig. 2A), pointing again at the
importance of this proline residue.We also checked the eﬀect of the Pﬁ H mutation on
MyD88 homodimerisation (Fig. 2B). When using full-length
MyD88 as bait and prey, mutation of both TIR domains did
not aﬀect interaction, whereas binding of the MyD88TIR-prey
was completely lost when using MyD88P200H as a bait. These
results indicate that the death domain of MyD88 is not only
important in recruiting downstream signalling molecules, but
also for MyD88 homodimerisation.
3.3. Mal bridges TLRs to MyD88
We next examined the TLR4 interaction proﬁle using the
intracellular part of TLR4 as bait (TLR4ic) and diﬀerent
TLR adaptors as prey (Fig. 3A). As expected, clear interaction
was seen between TLR4ic and Tram, conﬁrming its unique
function in TLR4 signalling [13,14]. Mal/TIRAP also bound
to TLR4ic, an interaction which was reported before [8]. Co-
transfection of the TLR4ic-bait and the universal TLR adap-
tor MyD88-prey did not result in any luciferase induction
although the role of MyD88 in TLR4 signalling is very well
documented [28,29]. Therefore, we examined if the MyD88-
TLR4 interaction could be indirect (Fig. 3B). Co-transfection
of a Mal expression vector together with TLR4ic-bait and
MyD88-prey resulted in a clear luciferase induction, indicating
that Mal bridges MyD88 to TLR4. This interaction was com-
pletely lost when using the TIR disrupting Mal (MalP125H) or
MyD88 (MyD88P200H) mutations, pointing at the impor-
tance of the diﬀerent TIR domains in this interaction.
Table 1
Overview of primers used in this study
Primer 1 5 0-GCGAATTCATGGCTGCAGGAGGTCCCGGCG-3 0
Primer 2 5 0-GCGCTCTAGATCAGGGCAGGGACAAGGCCTTGG-3 0
Primer 3 5 0-GCGGTAACCGTGCCGCCATGGACCCCCTGGGGCATATGCC-30
Primer 4 5 0-GCTCTAGACAGTCAGGGCAGGGACAAGGCC-3 0
Primer 5 5 0-GCGAATTCATGGCATCATCGACCTCC-30
Primer 6 5 0-GCGCTCTAGACTCAAAGTAGATCAGATAC-30
Primer 7 5 0-GCGGTAACCGTGCCGCCATGGGCAGTAGTCGCTGGAGC-30
Primer 8 5 0-GCTCTAGACAGTCAAAGTAGATCAGATACTGT-30
Primer 9 5 0-GCGCGAATTCACTCCAGATGTCTTCATCAGC-30
Primer 10 5 0-GGCCTCTAGATTAGCGGCCCTGCAGGAAGCGG-30
Primer 11 5 0-GCGGTAACCGCCGCCATGGATTACAAGGATGACGACGATAAGGGTATC GGAAGTCTAAAATAAATTCC-3 0
Primer 12 5 0-GCCTCGAGTCAGGCAATAAATTGTCTTTGTACC-3 0
Primer 13 5 0-GCGGATCCATGGCTGCAGGAGGTCCCGGC-30
Primer 14 5 0-GCGCGGCCGCTCAGGGCAGGGACAAGGCC-30
Primer 15 5 0-GCGAGCTCCGGATCCATGGCATCATCGACCTCC-3 0
Primer 16 5 0-ATAGTTTAGCGGCCGCTCACCGTAGATCAGATAC-30
Primer 17 5 0-GCCGGGATCCATGGGTATCGGGAAGTC-3 0
Primer 18 5 0-GCCGATGCGGCCGCTCAGGCAATAAATTGTC-30
Primer 19 5 0-GCGGATCCTGCCACCGTTTCCATGG-30
Primer 20 5 0-GCGCGGCCGCCTAGGACTTTATCG-30
Primer 21 5 0-GCGAGCTCGTCTTTTTATTGGAATG-30
Primer 22 5 0-GCGCGGCCGCTTAATGTACAGAGTTTTTGG-3 0
Primer 23 5 0-GCGGATCCTGCATAAAGTATGGTA-30
Primer 24 5 0-GCGCGGCCGCTCAGATAGATGTTGC-30
Primer 25 5 0-GCGGATCCACAAAGTTCCGGGGCTTCTG-30
Primer 26 5 0-CCGGCCGCGGCCGCCTTAGGAGATGGTTGCTAC-3 0
Primer 27 5 0-GCGGATCCCACCTCTATTTCTGGGATGT-30
Primer 28 5 0-CCGGCCGCGGCCGCCCTAGACCGTTTCCTTGAACACC-30
Primer 29 5 0-GCGCGCGGATCCTGGCGGGGGCGGCAAAGTGG-30
Primer 30 5 0-CCGGCCGCGGCCGCCCTATTCGGCCGTGGGTCCC-30
Primer 31 5 0-GCAACTCCGGGATGCAACCCACGGCGGCGCTATAGTGTCC-30
Primer 32 5 0-GGACACTATAGCGCCGCCGTGGGTTGCATCCCGGAGTTGC-30
Primer 33 5 0-GTCTGACCGCGATGTCCTCCATGGCACCTGTGTCTGGTC-30
Primer 34 5 0-GACCAGACACAGGTGCCATGGAGGACATCGCGGTCAGAC-30
Primer 35 5 0-GCGAGGTACCGCCACCATGGCCCAGCACGA-3 0
Primer 36 5 0-GCAGCGGCCGCTTAGAGTTGGAAGGGGTACTG-30
Primer 37 5 0-GCGCGAATTCATGGCATCATCGACCTCCC-30
Primer 38 5 0-GCCGCTGCGGCCGCTCAAAGTAGATCAGATACTGTAGC -30
Table 2
Overview of tested adaptor/adaptor and adaptor/TLR interactions
Mal MalTIR MyD88 MyD88TIR Tram SarmTIR SVT
Prey
Mal 8.53 2.54 19.19 11.55 2.3 4.57 1.68
MyD88 23.77 44.84 19.99 45.14 1.05 12.15 2.30
Tram 2.59 2.01 1.33 1.25 18.66 11.66 2.46
Bait
TLR2ic 8.71 8.18 2.28 0.92 1.06 2.79 1.04
TLR3ic 4.01 3.07 1.01 0.99 1.16 4.43 1.22
TLR4ic 26.69 56.65 1.22 1.05 16.40 1.70 1.22
Hek293T cells were transiently co-transfected with the MAPPIT bait plasmid (0.5 lg), diﬀerent TLR adaptor prey plasmids (0.5 lg) and the STAT3
responsive rPAPI-luci reporter (0.3 lg). Twenty-four hours after transfection the transfected cells were stimulated with leptin (100 ng/ml) for another
24 h or were left untreated (NS). Luciferase measurements were performed in triplicate. Data are expressed as mean fold induction (ratio Stimulated/
NS). Positive interactions (fold induction >5) are highlighted in bold. SVT-prey was used as a negative control. Expression of all the diﬀerent preys
was checked by Western blot analysis using an anti-FLAG antibody.
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The extracellular portion of the leptin receptor was used to
immunoprecipitate the MAPPIT TLR4ic-bait protein (using an
anti-LR antibody) and only when Mal was co-expressed, the
MyD88-prey protein could be co-immunoprecipitated.
In an analogous manner, the TLR2ic interaction proﬁle was
examined (Fig. 3D). In accordance with the TLR4ic interac-
tion proﬁle, no interaction between MyD88 and TLR2 could
be observed. However, complementation with Mal gave riseto a clear luciferase induction, indicating that Mal also acts
as bridging adaptor between MyD88 and TLR2.4. Discussion
One of the ﬁrst steps in pathogen recognition and clearance
is the recognition of evolutionary conserved pathogen-associ-
ated molecular patterns whereby TLRs play a crucial role.
Fig. 2. Mal and MyD88 homo- and heterodimersiation. (A) Hek293T cells were transiently co-transfected with the MAPPIT bait plasmid pCLL-
Mal or pCLL-MalP125H, diﬀerent TLR adaptor prey plasmids and the STAT3 responsive rPAPI-luci reporter. Experimental setup was as in Table
2. (B) Interaction analysis of the MyD88 bait (pCLL-MyD88) or its mutant (pCLL-MyD88P200H). Experimental setup was as in Table 2.
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pathways, ultimately leading to pro-inﬂammatory responses.
These responses vary between activated TLRs, which is in part
explained by diﬀerent adaptor usage. We here take a closer
look at the mechanistics of TLR adaptor recruitment using
MAPPIT, a mammalian two-hybrid strategy. We cloned all
known TLR adaptors either as bait or as prey, and the intra-
cellular part of selected TLRs as bait. As shown in Table 2,
well-documented interactions like MyD88/Mal homo- and het-
ero-dimerisation, or recruitment of Tram to TLR4 could read-
ily be detected. No interactions were observed using Trif as a
bait or as a prey, probably due to its unique, non-cytoplasmic
localisation that most likely interferes with the MAPPIT read-
out (Fig. 1B). Next to known interactions, some new observa-
tions were also found. Recently, Sarm was described as a
negative regulator of Trif-dependent signalling pathways [15].
However, as seen in Table 2, we also observed a clear interac-
tion with MyD88 or Tram when using the ‘TIR’ interaction
domain of Sarm as a prey. These data suggest that Sarm, nextto inhibition of Trif , also could be involved in regulating the
TLR adaptors MyD88 and Tram.
MyD88 is commonly referred to as a ‘‘universal’’ adaptor,
used by every TLR except TLR3. However, biochemical data
providing a direct link between MyD88 and a TLR are scanty.
In this report we could not detect an interaction between
MyD88 and TLR2, TLR4 (Fig. 3). However, the TLR4-bait
is fully functional since a clear signal was obtained for the
well-documented interactions with the Mal- or Tram-preys
[13,14]. This inability of MyD88 to bind TLR4 in MAPPIT
is in line with a recent report showing no MyD88/TLR4 bind-
ing when analyzed via the yeast two-hybrid method [30]. Sig-
niﬁcantly, co-expression of the TLR adaptor Mal resulted in
a clear MAPPIT signal for the TLR4-bait/MyD88-prey combi-
nation. Since Mal binds both TLR4 and MyD88, this observa-
tion demonstrates its bridging role between MyD88 and
TLR4, analogous to the Tram/Trif branch of TLR4 signal-
ling [31] (Fig. 3B). These data were conﬁrmed using co-immu-
noprecipitation (Fig. 3C). While this manuscript was in
Fig. 3. TLR4ic interaction proﬁle. (A) Hek293T cells were transiently co-transfected with the MAPPIT bait plasmid pCLL-TLR4ic, various TLR
adaptor prey constructs (or a SVT-prey as negative control) and the rPAPI-luci reporter. Experimental setup was as in Table 2. (B) Eﬀect of a Mal
expression vector. Hek293T cells were transiently co-transfected with pCLL-TLR4ic, a MyD88-prey (pMG2-MyD88/pMG2-MyD88P200H), a Mal
expression vector (pcDNA5-Mal/pcDNA5-MalP125H) and the rPAPI-luci reporter. Experimental setup was in Table 2. (C) Co-immunoprecipitation
analysis. Hek293T cells were transfected with combinations of pCLL-TLR4ic, pMG2-MyD88, pDC304-Mal-HA. Cell lysates were immunopre-
cipitated with an a mixture of two rat monoclonal antibodies against the extracellular part of the leptin receptor (a-LR) and subsequently
immunoblotted (IB) with anti-ﬂag or anti-HA. (D) TLR2ic interaction proﬁle. Hek293T cells were transiently co-transfected with the MAPPIT bait
plasmid pCLL-TLR2ic, various TLR adaptor prey constructs, a Mal expression vector (or empty vector) and the rPAPI-luci reporter. Experimental
setup was as in Table 2.
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a PIP2 binding domain that mediates Mal recruitment to mem-
branes and that the primary function of Mal in TLR signalling
is to facilitate MyD88 delivery to TLR4 via PIP2 binding [27].
These observations are also consistent with the phenotype of
Mal-deﬁcient mice, which is analogous to MyD88-deﬁcient
mice in terms of TLR2 and 4 signalling [7,10]. Similar ﬁndings
were obtained supporting a TLR2/Mal/MyD88 bridging com-
plex (Fig. 3D) in line with the need for Mal in TLR2 signalling.
Of note, our ﬁndings are in contrast with a recent report [30],
demonstrating direct TLR2/MyD88 binding with a yeast two-
hybrid approach. The reason for this contradictory ﬁnding is
unclear at present.
We also evaluated the interactions between the TIR domains
of additional TLRs (TLR5, TLR7 and TLR 9) and MyD88
(data not shown). Most interestingly, in none of these cases
could we observe any signal. Although we cannot rule out at
present that our strategy fails to detect these interactions, we
would like to point out that a control using a JAK2-binding-
prey was clearly positive, indicating that the attached TIR do-mains did not interfere with the MAPPIT read out. Moreover,
the yeast two-hybrid method also failed to detect direct inter-
action between TLR9 and MyD88 [30]. In addition, TLR7 and
TLR9 signal from acidic endosomes. How MyD88 is recruited
to those distinct cellular compartments remains unknown, and
the use of accessory molecules, next to Mal and Tram, there-
fore cannot be excluded.
We next investigated the dimerisation properties of Mal
and MyD88 in more detail. MyD88 and Mal both are two-
domain proteins containing a C-terminal TIR domain
preceded by a Death Domain and a N-terminal domain,
respectively. Mutation of a single proline to histidine in the
so called ‘‘BB-loop’’ of the TIR domain blocks TLR signal-
ling. Various models of these TIR domains have been
described, but the precise role of this conserved proline
remains elusive [32,33]. Strikingly, mutation of the TIR do-
main of Mal (MalP125H) in either prey or bait, contrary to
GST pull-down experiments [32], completely abolishes homo-
dimerisation (Fig. 2A). These data support the model in
which the BB loop of the TIR domain plays a crucial role
P. Ulrichts et al. / FEBS Letters 581 (2007) 629–636 635in TIR-TIR interactions [33] and provide a biochemical expla-
nation for the drastic eﬀect of this mutation on signalling.
Moreover, in contrast with wild type Mal-bait, the
MalP125H-bait is no longer capable of activating NF-jB sig-
nalling (Fig. 1C). This again reﬂects the importance of this
proline residue in TLR signalling. In addition, we observed
that the contribution of each interaction domain of Mal
and MyD88 diﬀers from homo- and hetero-dimerisation.
For hetero-dimerisation, the isolated TIR domain of Mal or
MyD88 is suﬃcient (Fig. 2). Mal homodimerisation on
the other hand is dependent on the N-terminal domain of
Mal, which is necessary to stabilise homodimer formation
(Fig. 2A). This contrasts to MyD88 homodimerisation
(Fig. 2B), where the isolated TIR domain is suﬃcient for
interaction. Mutation of the conserved proline residue in the
isolated TIR domain again abolished interaction. In contrast,
full-size bait and prey homodimerisation is not aﬀected by
this P200H mutation nor does it eliminate NF-jB signalling
(Fig. 1C). This implies that the MyD88 Death Domain not
only interacts with downstream signalling molecules, as
shown in several studies [17], but also can participate in
MyD88 homodimer formation.
In brief, we examined the recruitment and dimerisation
properties of the TLR adaptors Mal and MyD88 and provide
a biochemical basis for the bridging function of Mal between
an activated TLR and the TLR adaptor MyD88.
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